What you need to know to understand Alexey Navalny, one of Vladimir Putin’s loudest critics
How some North Dakota farmers and two former Cheesecake Factory execs are reinventing casual dining
Campaigns to raise the minimum wage are finally coming to fruition
The Salesforce.com CEO is pushing his fellow tech billionaires into giving back to the city
From the U.S. jobless rate to the ruble to pollution in Beijing, here are 10 key indicators that you'll want to keep an eye on
Irate parents find an "extruding tool" for decorating cakes unsavory
Reward points suffer from inflation, too. Here are three strategies for getting the most out of the points you have, before their value falls
"No place to rage quite like the Kasper Multipurpose Room," one student gripes
The Zappos CEO is spending $350 million to build a startup paradise in downtown Las Vegas. It hasn't been all unicorns and butterflies
Founders: Jeff Stein, John Finn, and John Schmid
VC Investment over the last four quarters: $35.16 million
Founded in 2004, the 35-employee biopharmaceutical company is working to develop antibacterial drugs to treat infections caused by resistant bacteria. Besides the VC investment, Stein says Trius has raised $32 million in government grants and contracts. As far as his perspective on the impact of the recession on his company, which expects less than $1 million in revenues in 2008, Stein says it will make the fundraising environment more challenging and may impact the partner environment as well.
Key to startup success: "Recruit top-tier executives. Focus on advancing your most valuable asset and seek alternative financing for earlier-stage programs."